Vivos Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Update
Vivos Therapeutics reported Q3 2026 revenue of $6.4 million, up 24% quarter-over-quarter, with operating loss improving 18% year-over-year to $3.9 million. The company reduced annual operating costs by $5 million, exchanged $6.1 million of debt for equity, and regained Nasdaq compliance with stockholders' equity requirements following the October 2026 SOD Sciences acquisition. Management expects new clinical initiatives and payer contract renegotiations to contribute to revenue growth beginning Q4 2026.


